Roivant Sciences showcased an active quarter marked by significant pipeline developments, including a new cutaneous ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against other best stocks to buy according to billionaire David Einhorn. David Einhorn is a highly ...

Roivant Sciences Ltd. has seen a slight gain of 10% in its stock over the past 10 months, since my "buy" recommendation last May. The company has a differentiated drug development pipeline ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other best mid cap biotech stocks to buy. On March 6, Jared Holz, Mizuho health care ...

Access Roivant Sciences stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

Roivant Sciences BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has ...

Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready pulmonary hypertension drug. The asset in question ...

A substantial insider activity was disclosed on October 23, as Venker, President & COO at Roivant Sciences (NASDAQ:ROIV), reported the exercise of a large sell of company stock options.

We're going with our next company presenter at the BofA Annual Healthcare Conference. I am pleased to be introducing Roivant ...

Investing.com — Mercredi 14 mai 2025, Roivant Sciences (NASDAQ:ROIV) a présenté lors de la conférence BofA Securities 2025 Healthcare, offrant un aperçu de ses priorités stratégiques. L’entreprise a m ...

Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades ...